bluebird bio
NEWS
Bluebird bio announced interim data from two different two-year clinical trials of LentiGlobin gene therapy for transfusion-dependent beta-thalassemia (TDT).
Celgene and bluebird bio have inked a development and promotion deal for bb2121, bluebird’s B-cell maturation antigen (BCMA) CAR-T therapy for relapsed/refractory multiple myeloma (rrMM).
A look at three small biotechs that big drugmakers are drooling over.
Here are five possible acquisition targets to keep an eye on.
Having a stock double in value is a good thing.
Many investors and analysts expect that the changes to the corporate tax code will lead to increased merger and acquisition activity in 2018.
Plenty of companies had interesting news to share at the J.P. Morgan Healthcare Conference in San Francisco this week, and bluebird bio received more attention than some.
As yet, the company has no products on the market, so the applications, if approved, would mark the company’s shift into a commercial company.
Juno Therapeutics is now the “cheapest” player now developing CAR-T cancer medications, an analyst said Wednesday as he downgraded rival Bluebird Bio.
JOBS
IN THE PRESS
First gene therapy recommended for approval in the EU for TDT
A third party press release was issued stating that the EMA issued an approval for the conditional Marketing Authorization Application for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia.
Gov. Cooper to cut ribbon on facility that will strengthen bluebird bio’s capabilities to manufacture products for clinical development and commercial supply
bluebird bio, Inc. announced that members of the management team will present at the following upcoming investor conferences
bluebird bio, Inc. reported financial results and business highlights for the fourth quarter and full year ended December 31, 2018.
CFO with proven track record will help lead transition to commercial company
The small size of sdAbs may enable the generation of more complex CAR T cell products such as those designed to combine additional functions into a single CAR molecule or recognize multiple tumor antigens simultaneously.
LentiGlobin treatment-derived hemoglobin HbAT87Q equals or exceeds sickling hemoglobin (HbS) levels in Group C patients at six months post treatment
First presentation of data from patients with a β0/β0 genotype and a pediatric patient treated with LentiGlobin in Phase 3 Northstar-3 study both have stopped chronic blood transfusions
bb21217 early safety profile consistent with CAR T platform therapies